News | April 19, 2025
GSK’s blenrep combinations approved by UK MHRA in relapsed/refractory multiple myeloma
Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed
Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed
If approved, Blenrep (belantamab mafodotin) in combinations with BorDex (BVd) and PomDex (BPd) could redefine multiple myeloma treatment at or after first relapse
Statistically significant and clinically meaningful reduction in the risk of death seen with Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex
Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex
Momelotinib complements GSK’s existing expertise in haematology, with Sierra Oncology anticipating US regulatory submission in Q2 this year and EU submission in the second half of 2022
Subscribe To Our Newsletter & Stay Updated
